PerkinElmer newborn screening test gets CE Mark

2020 09 30 21 25 9123 Perkin Elmer Headquarters 400

PerkinElmer has received the CE Mark for its reverse transcription polymerase chain reaction (RT-PCR) newborn screening assay.

The company's Eonis test screens for spinal muscular atrophy, severe combined immunodeficiency, and X-linked agammaglobulinemia in newborns and will be integrated into PerkinElmer's sample-to-result workflow.

Page 1 of 10
Next Page